COPENHAGEN, Dec 18 (Reuters) - The European Union's drug

regulator said it would assess two new Danish studies that link

Novo Nordisk's popular diabetes drug Ozempic to a

rare eye disease.

The studies published earlier this week had found Ozempic

significantly increases the risk of type 2 diabetes patients

developing NAION (non-arteritic anterior ischemic optic

neuropathy), more than doubling the likelihood.

The European Medicines Agency (EMA) said late on Tuesday

that the reviewed evidence from other research so far had not

been strong enough to suggest a possible link between Ozempic

and the eye disease but that the two Danish studies may hold new

important information.